Christopher Dvorak is an Oncology physician affiliated with City College of San Francisco. OpenAlex indexes 422 publications with 12,729 citations (h-index 58); ClinicalTrials.gov lists 4 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Pediatric Hematology-Oncology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
725 Welch Rd
Palo Alto, CA 943041601
Telephone
650-723-4000Registry record last updated 24 Mar 2008.
Clinical trials
- A Feasibility Study Using CLINIMACS® for Alpha/Beta T-Cell Depletion in Stem Cell Transplant
Sponsor: Christopher Dvorak
- JSP191 Antibody Targeting Conditioning in SCID Patients
Sponsor: Jasper Therapeutics, Inc.
- Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation
Sponsor: University of California, San Francisco
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
10 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Alexion Pharmaceuticals, Inc.Program year202512 payments$38,713openpaymentsdata.cms.gov ↗
- Mesoblast, Inc.Program year20252 payments
- SOBI, INCProgram year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
2 NIH research awards on record, funded 2014–2025 per NIH RePORTER. The latest:
- Primary Immune Deficiency Treatment Consortium (PIDTC): A resource to drive scientific and clinical advances related to the treatment of inborn errors of immunity
University of California, San Francisco
FY2025$1,743,065R24AI184316 - Primary Immune Deficiency Treatment Consortium (PIDTC): A resource to drive scientific and clinical advances related to the treatment of inborn errors of immunity
University of California, San Francisco
FY2025$21,475R24AI184316 - Primary Immune Deficiency Treatment Consortium (PIDTC): A resource to drive scientific and clinical advances related to the treatment of inborn errors of immunity
University of California, San Francisco
FY2024$1,815,882R24AI184316
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- The diagnosis of severe combined immunodeficiency (SCID): The Primary Immune Deficiency Treatment Consortium (PIDTC) 2022 Definitions
Journal of Allergy and Clinical Immunology
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Sima Porten, MD
City College of San Francisco
Nalin Gupta, MD
City College of San Francisco
Trever Bivona, MD, PhD
City College of San Francisco
Ethan Winkler, MD, PhD
City College of San Francisco
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”